Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of the WHIST trial are in!

WHIST

Incisional negative-pressure wound therapy does not provide a benefit compared to standard wound dressings for surgical incisions associated with major trauma to the lower limbs.

Major trauma is the leading cause of death worldwide in people under 45 and a significant cause of short- and long-term disability. In the context of major trauma, the wounds associated with surgery to fractured limbs are notoriously difficult to manage and serious wound healing complications such as deep surgical site infection (SSI) are common.

The WHIST trial investigated whether the type of dressing applied over the wound at the end of the operation can reduce the rate of infection. However, no significant difference in rate of infection between Negative Pressure Wound Therapy (NPWT) and standard dressing was identified.

WHIST was a randomised, controlled, superiority trial which randomised 1548 participants to either NPWT or standard wound dressing in a 1:1 ratio. Rates of deep SSI at 30 days post-randomisation were similar for both treatments (6.7% in the standard dressing group vs. 5.8% in the NPWT group) and there was no statistically significant difference between the groups (risk difference -0.8%; 95% CI -3.2% to 1.7%). There was also no significant difference between the two groups in terms of disability, quality of life or scar appearance at 3 or 6 months post-randomisation.

 

The monograph publication for the WHIST trial can be found here.

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.